Friday, May 21, 2021 Daily Archives

The Pandemic Changes Facility Strategy: A Focus on Speed to Market Triggers Innovation

by

The push to expedite COVID-19 vaccines over the past year has led the biopharmaceutical industry to try novel strategies to accelerate product development and manufacturing. To compress discovery, development, and manufacturing into several months rather than a typical multiple-year effort has meant reexamining nearly every aspect of the process — including facilities required to house the work. Successful COVID-19 vaccine development undoubtedly will change biomanufacturing strategy forever. Previously, current good manufacturing practice (CGMP) manufacturing options were twofold: building facilities and…

May 21, 2021

Cryoport increases global supply chain with F-Airgate acquisition

by

Cryoport will expand its presence in the EMEA region through the acquisition of Belgium-based temperature-controlled supply chain solutions firm F-Airgate. Cryoport, a temperature-controlled supply chain services company for the life sciences, has agreed to buy F-airgate, which will join Cryoport’s CRYOPDP business unit. No financial details have been divulged. “This acquisition will expand our coverage in Europe and enable us to provide end-to-end solutions to both global and local customers in Belgium, which is a highly strategic area for Pharma/BioPharma activity in Europe, 

May 21, 2021

Achilles turns to Autolomous digital tech to support T cell programs

by

Achilles Therapeutics will use a customized digital manufacturing system to support its T cell therapy programs. Developer and manufacturer of management systems for cell and gene therapies Autolomous will supply a bespoke version of its AutoIoMATE technology to T cell developer Achilles. Terms of the partnership have not been disclosed. “The AutoloMATE platform is an out-of-the-box system, which we configure and validate for the individual requirements of our customers,†Kwok Pang chief operating officer at Autolomous told BioProcess Insider. “Autolomous continually…

May 21, 2021

N-SIDE launches app to optimize clinical manufacturing supply chain

by

The Production App has already saved one biopharma firm €10.5 ($12.8) million by optimizing manufacturing planning within the uncertainty of the R&D process, says N-SIDE. N-SIDE has a suite of software aimed at optimizing the entire clinical trial supply chain management process from production planning through to protocol design and delivery of supplies to patients. The latest offering, known as ‘The Production App,’ focuses on helping biopharma firms manage the complexities and uncertainties of manufacturing clinical material and according to the…

May 21, 2021

Bayer subsidiary Bluerock teams to develop cell therapies for eye diseases

by

BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics have formed an R&D alliance to develop cell therapies for ocular diseases. The collaboration will see the firms merge their different expertise to discover and develop off-the-shelf induced pluripotent stem (iPS) cell therapies. “This collaboration represents a step forward in building a portfolio of best-in-class cellular medicines with the potential to change the treatment paradigm and become standard of care for degenerative retinal diseases,†Emile Nuwaysir CEO at BlueRock told BioProcess Insider.…

May 21, 2021

Thermo teams with UCSF on San Fran cell therapy center

by

Thermo Fisher Scientific has teamed up with the University of California, San Francisco (UCSF) to set up a cell therapy manufacturing center. The facility – which will be at USCF’s Mission Bay campus in San Francisco – will offer clinical and commercial cGMP cell therapy manufacturing services and technology development support. According to Thermo Fisher, the facility, which is due to open next year, will serve as a central location where customers and UCSF researchers will have access cell therapy systems, reagents,…

May 21, 2021